Aktienanalyse zu Edwards Lifesciences Corp (EW)EWEdwards Lifesciences Corp

Edwards Lifesciences Corporation is a global structural heart company. The Company's work includes both surgical and transcatheter therapies. Its portfolio of repair and replacement technologies for aortic, mitral, tricuspid and pulmonic heart valves provides a set of treatment options to serve the diverse and complex patients in need. Its segment includes the United States, Europe, Japan, and the Rest of World. Its product categories include Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical. It provides transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. Its products include SAPIEN 3 Ultra RESILIA transcatheter heart valve, SAPIEN 3 Ultra transcatheter heart valve, SAPIEN 3 transcatheter heart valve and Alterra adaptive prestent. The TMTT category includes a PASCAL transcatheter repair system, EVOQUE tricuspid valve replacement system and others. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Edwards Lifesciences Corp is a good buy right now due to its current price of $86.6, which is well below the average analyst price target of $101.57, suggesting a potential upside of approximately 17.3%. Additionally, the forward P/E ratio is 25.641, indicating reasonable valuation compared to its growth prospects. The main risk is the recent decline in net income, which dropped to $241.9 million in Q2 2026 from $380.7 million in Q1 2026, reflecting a potential volatility in earnings.

21 analysts cover EW: 16 rate it Buy, 4 Hold and 1 Sell. The average price target is 96.52.